|
[1] Chiness Society of Hepatology,Chinese Medical Association.Guidelines for the the diagnosis and management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089.
|
|
[2] RIDOLA L,NARDELLI S,GIOIA S,et al. Quality of life in patients with minimal hepatic encephalopathy[J]. World J Gastroenterol,2018,24(48):5446-5453.
|
|
[3] LAURIDSEN MM,THACKER LR,WHITE MB,et al. In patients with cirrhosis,driving simulator performance is associated with real-life driving[J]. Clin Gastroenterol Hepatol,2016,14(5):747-752.
|
|
[4] GUO JS. Epidemiology diagnosis and treatment of minimal hepatic encephalopathy[J]. Chin J Hepatol,2014,22(2):92-93.(in Chinese)郭津生．重视轻微型肝性脑病的流行病学及诊断与治疗[J]．中华肝脏病杂志，2014,2(22):92-93.
|
|
[5] AMPUERO J,MONTOLIU'C,SIMN-TALERO M,et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression[J]. J Gastroenterol Hepatol,2018,33(3):718-725.
|
|
[6] HANAI T,SHIRAKI M,WATANABE S,et al. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan:A propensity score-matching analysis[J]. J Gastroenterol Hepatol,2019,34(10):1809-1816.
|
|
[7] FLAMM SL. Considerations for the cost-effective management of hepatic encephalopathy[J]. Am J Manag Care,2018,24(4 Suppl):s51-s61.
|
|
[8] NABI E,BAJAJ JS. Useful tests for hepatic encephalopathy in clinical practice[J]. Curr Gastroenterol Rep,2014,16(1):362.
|
|
[9] SEN J,BELLI A. S100B in neuropathologic states:The CRP of the brain?[J]. J Neurosci Res,2007,85(7):1373-1380.
|
|
[10] IKEDA Y,UMEMURA K. Analysis of reference values of serum S100B concentrations of Japanese adults[J]. Rinsho Byori,2005,53(5):395-399.
|
|
[11] ZETTERBERG H,BLENNOW K. Fluid biomarkers for mild traumatic brain injury and related conditions[J]. Nat Rev Neurol,2016,12(10):563-574.
|
|
[12] DUARTE-ROJO A,RUIZ-MARGIN A,MACIAS-RODRIGUEZ RU,et al. Clinical scenarios for the use of S100βas a marker of hepatic encephalopathy[J]. World J Gastroenterol,2016,22(17):4397-4402.
|
|
[13] KAWATA K,RUBIN LH,TAKAHAGI M,et al. Subconcussive impact-dependent increase in plasma S100βlevels in collegiate football players[J]. J Neurotrauma,2017,34(14):2254-2260.
|
|
[14] GLE爦E,IOSIFESCU DV,TURAL．Plasma Neuronal and glial markers and anterior cingulate metabolite levels in major depressive disorder:A Pilot Study[J]. Neuropsychobiology,2020,79(3):214-221.
|
|
[15] SAKDEJAYONT S,PRUPHETKAEW N,CHONGPHATTARAROT P,et al. Serum S100βas a predictor of severity and outcomes for mixed subtype acute ischaemic stroke[J]. Singapore Med J,2020,61(4):206-211
|
|
[16] GIMENEZ-GARZC,URIOS A,AGUSTA,et al. Is cognitive impairment in cirrhotic patients due to increased peroxynitrite and oxidative stress?[J]. Antioxid Redox Signal,2015,22(10):871-877.
|
|
[17] DARWISH RS,AMIRIDZE N,AARABI B. Nitrotyrosine as an oxidative stress marker:Evidence for involvement in neurologic outcome in human traumatic brain injury[J]. J Trauma,2007,63(2):439-442.
|
|
[18] MONTOLIU C,CAULI O,URIOS A,et al. 3-nitro-tyrosine as a peripheral biomarker of Minimal hepatic encephalopathy in patients with liver cirrhosis[J]. Am J Gastroenterol,2011,106(9):1629-1637.
|
|
[19] LI J,ZHAO JM,ZHANG L,et al. Diagnostic value of 3-nitrotyrosine for minimal hepatic encephalopathy[J]. J Clin Neurol,2019,32(1):25-28.(in Chinese)李洁，赵江明，张丽，等．3-硝基酪氨酸对轻微型肝性脑病的诊断价值[J]．临床神经病学杂志，2019,32(1):25-28.
|
|
[20] ATTIA MS,AL-RADADI NS. Nano optical sensor binuclear Pt-2-pyrazinecarboxylic acid-bipyridine for enhancement of the efficiency of 3-nitrotyrosine biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy[J]. Biosens Bioelectron,2016,86:406-412.
|
|
[21] JAIN L,SHARMA BC,SHARMA P,et al. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy[J]. Dig Liver Dis,2012,44(12):1027-1031.
|
|
[22] DITISHEIM S,GIOSTRA E,BURKHARD PR,et al. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis[J]. BMC Gastroenterol,2011:134.
|
|
[23] HERR DR,CHEW WS,SATISH RL,et al. Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases[J]. Mol Neurobiol,2020,57(1):372-392.
|
|
[24] MASAGO K,KIHARA Y,YANAGIDA K,et al. Lysophosphatidic acid receptor,LPA(6),regulates endothelial bloodbrain barrier function:Implication for hepatic encephalopathy[J]. Biochem Biophys Res Commun,2018,501(4):1048-1054.
|
|
[25] SHAO X,UOJIMA H,SETSU T,et al. Usefulness of autotaxin for the complications of liver cirrhosis[J]. World J Gastroenterol,2020,26(1):97-108.
|
|
[26] LI D,ZHANG CJ. Expression and significance of lysophosphatidic acid receptor and autocrine motor factor in patients with liver cirrhosis and hepatic encephalopathy[J]. Chin Hepatol,2020,25(3):313-316.(in Chinese)李丹，张长江．溶血磷脂酸受体、自分泌运动因子在肝硬化肝性脑病患者中的表达及意义[J]．肝脏，2020,25(3):313-316.
|
|
[27] ALDRIDGE DR,TRANAH EJ,SHAWCROSS DL. Pathogenesis of hepatic encephalopathy:Role of ammonia and systemic inflammation[J]. J Clin Exp Hepatol,2015,5(Suppl 1):s7-s20.
|
|
[28] KIM YS,LEE KJ,KIM H. Serum tumour necrosis factor-αand interleukin-6 levels in Alzheimer’s disease and mild cognitive impairment[J]. Psychogeriatrics,2017,17(4):224-230.
|
|
[29] NG A,TAM WW,ZHANG MW,et al. IL-1β，IL-6,TNF-αand CRP in elderly patients with depression or Alzheimer’s disease:Systematic review and meta-analysis[J]. Sci Rep,2018,8(1):12050.
|
|
[30] CHEN JM,JIANG GX,LI QW,et al. Increased serum levels of interleukin-18,-23 and-17 in Chinese patients with Alzheimer’s disease[J]. Dement Geriatr Cogn Disord,2014,38(5-6):321-329.
|
|
[31] MONTOLIU C,PIEDRAFITA B,SERRA MA,et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy[J]. J Clin Gastroenterol,2009,43(3):272-279.
|
DownLoad: